In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $1.44 in the prior trading day, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $1.35, down -6.25%. In other words, the price has decreased by -$6.25 from its previous closing price. On the day, 0.71 million shares were traded. ZNTL stock price reached its highest trading level at $1.445 during the session, while it also had its lowest trading level at $1.34.
Ratios:
Our goal is to gain a better understanding of ZNTL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.13.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.
Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 97135072 and an Enterprise Value of -193157888. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.62 while its Price-to-Book (P/B) ratio in mrq is 0.33. Its current Enterprise Value per Revenue stands at -7.19 whereas that against EBITDA is 0.969.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.73, which has changed by -0.6529563 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $5.44, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is 0.31%, while the 200-Day Moving Average is calculated to be -36.97%.
Shares Statistics:
The stock has traded on average 959.12K shares per day over the past 3-months and 548220 shares per day over the last 10 days, according to various share statistics. A total of 71.95M shares are outstanding, with a floating share count of 56.37M. Insiders hold about 21.66% of the company’s shares, while institutions hold 77.08% stake in the company. Shares short for ZNTL as of 1752537600 were 4766727 with a Short Ratio of 4.97, compared to 1749772800 on 5697118. Therefore, it implies a Short% of Shares Outstanding of 4766727 and a Short% of Float of 8.270001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
